The Relation of Urinary 8-OHdG, A Marker of Oxidative Stress to DNA, and Clinical Outcomes for Ischemic Stroke by Nakajima, Hideto et al.
  The Open Neurology Journal, 2012, 6, 51-57  51 
 
  1874-205X/12  2012 Bentham Open 
Open Access 
The Relation of Urinary 8-OHdG, A Marker of Oxidative Stress to DNA, 
and Clinical Outcomes for Ischemic Stroke 
Hideto Nakajima
1,2*, Ki-ichi Unoda
1,2, Takumi Ito
1, Haruko Kitaoka
1, Fumiharu Kimura
2, and  
Toshiaki Hanafusa
2 
1Department of Internal Medicine, Seikeikai Hospital, Sakai 590-0024, Japan  
2Department of Internal Medicine I, Osaka Medical College, Takatsuki 569-8686, Japan 
Abstract: Background: Oxidative stress/free radical generation after ischemic stroke contributes to neuronal cell injury. 
We evaluated the utility of an oxidative stress marker, urinary 8-hydroxy-2-deoxyguanosine (8-OHdG), to demonstrate an 
association between the changes of 8-OHdG and outcomes after acute ischemic stroke.  
Methods: We enrolled 44 patients (26 males and 18 females) who visited our hospital due to acute ischemic stroke. Urine 
was collected on admission and on Days 7, and 8-OHdG was measured by ELISA. The relationships between 8-OHdG 
levels, stroke subtypes, and clinical outcomes based on the NIHSS and modified Rankin Scale (mRS) upon discharge was 
evaluated.  
Results: In the overall cohort, the mean urinary level of 8-OHdG on Day 7 was increased than that on Day 0. The 8-
OHdG levels on Day 0 were not different between patients with poor and good outcomes. However, an increasing rate 
from Day 0 to 7 ( 8-OHdG) in stroke patients with a poor outcome (mRS ≥3) was significantly higher than those with a 
good outcome (mRS ≤2) (2.54 vs 39.44, p = 0.004).  
Conclusions: The biochemical changes related to 8-OHdG and oxidative stress may be considered a marker of ischemic 
brain injury and clinical outcome of ischemic stroke. 
Keywords: Ischemic stroke, Oxidative stress, 8-OHdG, Clinical outcome, Radical scavenger, Edaravone. 
1. INTRODUCTION 
  Oxidative  stress  is  one  of  the  mechanisms  involved  in 
ischemic brain injury induced by ischemia-reperfusion [1,2]. 
In addition to the direct cytotoxic effects of lipid peroxida-
tion,  oxidative  DNA  damage  occurs  immediately  after  is-
chemia-reperfusion  and  leads  to  ischemic  brain  injury,  as 
reflected by neural death and brain edema [3-7]. Thus, the 
burst of free radicals is thought to be associated with stroke 
severity. However, it remains uncertain how to evaluate the 
association between increased oxidative stress and functional 
outcomes  of  patients.  In  the  presence  of  oxidative  stress, 
reactive oxygen species, including superoxide anion radicals, 
hydrogen peroxide, and hydroxyl radicals, can cause oxida-
tive damage to lipids, proteins, and nucleic acids [8]. During 
oxidative stress, DNA is constantly being damaged and oxi-
datively modified. Nuclear and  mitochondrial DNA in tis-
sues  and  blood  lymphocytes  are  typical  sites  of  oxidation 
damage [8].  
  The  oxidatively  modified  product  8-hydroxy-2-
deoxyguanosine (8-OHdG) is one of the predominant forms 
of free radical-induced lesions of DNA. 8-OHdG can be de-
tected in human tissues or blood samples. Because oxidative  
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DNA lesions, i.e., oxidized nucleosides and bases, are rea-
sonably  water  soluble  and  excreted  into  the  urine  without 
being further metabolized, urinary 8-OHdG is considered an 
important  biomarker  of  generalized  and  cellular  oxidative 
stress [9]. In fact, urinary 8-OHdG levels have been most 
frequently measured to indicate the extent of oxidative dam-
age, since it is a non-invasive and technically less involved 
procedure [10]. 
  Edaravone  (3-methyl-1-phenyl-2-pyrazolin-5-one, 
Mitsubishi  Pharma
  Corp),  a  novel  radical  scavenger,  has 
been shown to inhibit lipid peroxidation and vascular endo-
thelial cell injury and ameliorate brain edema, tissue injury, 
delayed  neuronal  death,  and  neurological  deficits  [11-13]. 
Edaravone is the first neuroprotective agent to be approved 
for clinical use in Japan [14]. The effect of edaravone on 
ischemic processes has been investigated experimentally, but 
no data is available on its effects on oxidative stress markers 
in the human ischemic brain. 
  In  the  present  study,  we  examined  oxidative  stress  in 
patients  with  acute  ischemic  stroke  by  determining  the 
changes in urinary 8-OHdG, a maker of oxidative damage. 
We  evaluated  the  relationships  between  8-OHdG  levels, 
stroke subtypes, and clinical outcomes based on the National 
Institutes of Health Stroke Scale (NIHSS) and the modified 
Rankin Scale (mRS) at discharge. The effect of edaravone on 
oxidative
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2. MATERIALS AND METHODOLOGY 
2.1. Patients 
  Forty-four patients (males: 26, females: 18; age: 29–92 
years, mean ± SD: 71.3 ± 10.9 years) with acute cerebral 
infarction from July 2007 to February 2008 were enrolled in 
this  study  in  the  Department  of  Internal  Medicine  at 
Seikeikai Hospital, Sakai, Osaka. All patients underwent an 
MRI examination immediately at admission, and diagnosis 
was  based  on  clinical  findings.  An  NIHSS  score  was  as-
signed both at admission and upon discharge to determine 
neurological deficits [15]. The mRS was also used to assess 
their clinical outcomes at discharge [16]. Conventional vas-
cular  risk  factors  (hypertension,  diabetes  mellitus,  hyper-
lipidemia),  atrial  fibrillation, body  mass  index  (BMI)，and 
previous stroke  were evaluated. Patients whose data could 
not be evaluated at the time of stroke onset and those with 
hemorrhagic  infarction  were  excluded  from  this  study. 
Stroke  subtypes  were  defined  according  to  the  NINDS-III 
classification system [17]. Of the 44 patients, 9 (20.5%) had 
lacunar, 22 (50%) had atherothrombotic, and 13 (29.5%) had 
cardioembolic infarctions. Of these, 34 patients were treated 
with  edaravone  (3-methyl-1-phenyl-2-pyrazolin-5-one,  a 
free-radical scavenge, Mitsubishi Pharma Corp) in addition 
to routine treatment within 24 h of onset of symptoms (60 
mg/day for 14 days). The remaining patients did not receive 
edaravone, because this medical agent is relative contraindi-
cations for patients with chronic renal failure and has been 
approved for the treatment of acute ischemic stroke within 
24 hours after onset. All patients with lacunar and athero-
thrombotic infarctions received sodium ozagrel, a thrombox-
ane A2 synthetase inhibitor, intravenously (160 mg/day for 
10–14  days),  and  35  patients  received  glycerol  (250–500 
ml/day for 3–7 days). There was no patient with thrombolyt-
ic therapy in this study. This study received institutional re-
view  board  approval  and  informed  consent  was  obtained 
according to the Declaration of Helsinki. 
2.2. Measurement of Urinary 8-OHdG 
  Urine samples were collected on admission (Day 0) and 7 
days after admission (Days 7). Urinary 8-OHdG concentra-
tions were measured using an enzyme-linked immunosorbent 
assay (8-Hydroxydeoxyguanosine Check; Japan Institute for 
the Control of Aging, Shizuoka, Japan) [18]. Results were 
expressed  as  ratios  to  the  creatinine  contents  (per  mg  Cr) 
measured in the same samples. 
  Moreover, we evaluated the rate of change of oxidative 
stress( 8-OHdG) as:  8-OHdG (%) = (8-OHdG on Day 7 
8-OHdG on Day 0)/8-OHdG on Day 0. 
2.3. Statistical Analysis  
  Results are given as means ± SEs. Categorical variables 
were compared  using  the  
2 test and  continuous variables 
were compared  using the Mann-Whitney test or ANOVA, 
followed
 by Scheffe’s post hoc test. Significance levels were 
set at P < 0.05. 
 
3. RESULTS 
3.1. Urinary 8-OHdG and Relationships to Subtypes of 
Ischemic Stroke and Risk Factors for Arteriosclerosis 
  Patients  clinical  profiles  according  to  ischemic  stroke 
subtypes are summarized in Table 1. There were no signifi-
cant differences with respect to age or history of previous 
stroke among the 3 groups. Prevalence of auricular fibrilla-
tion  was  the  highest  among  those  with  cardiac  embolism. 
Regarding risk factors for arteriosclerosis, prevalence of hy-
pertension was the highest in patients with lacunar infarc-
tion, and incidence of diabetes mellitus and hyperlipidemia 
were the highest in those with atherothrombotic infarctions. 
The number of arteriosclerosis risk factors was also higher in 
lacunar and artherothrombotic infarction groups compared to 
cardioembolic  infarction  group.  The  cardioembolic  infarc-
tion group had a shorter time from onset to arrival, higher 
baseline NIHSS, and longer length of stay compared to the 
other 2 groups. There were no significant differences in 8-
OHdG concentrations on Day 0 among the 3 groups, and 8-
OHdG concentrations increased on Day 7 in all groups (Ta-
ble 1) 
  We investigated the relationship between 8-OHdG and 
stroke subtype, lacunar, atherothrombotic, and cardioembolic 
infarction. As shown in Fig (1), the increase in 8-OHdG in 
the  atherothrombotic  infarction  group  was  significantly 
greater than that in the lacunar infarction group (33.8 vs 6.3, 
p = 0.048). It was remarkable that Δ 8-OHdG in the athero-
thrombotic infarction group tended to be increased than that 
in the cardioembolic infarction group in spite of smaller vol-
ume of infarction for atherothrombotic infarction group. As 
shown in Table 1, patients with atherothrombotic infarction 
had more risk factors for arteriosclerosis than other groups. 
Also,  half  of  patients  with  atherothrombotic  infarction 
showed poor outcome (mRS ≥3). Since it was assumed that 
these risk factors might influence on a production of the oxi-
dative stress, we investigated whether risk factors for arterio-
sclerosis, hyperetension, diabetes mellitus and hyperlipidem-
ia,  and  body  mass  index  (BMI)  would  involve  theΔ  8-
OHdG.  As  results,  patients  with  diabetes  mellitus,  hyper-
lipidemia, or high BMI showed the increased 8-OHdG (p = 
0.047, p = 0.037, p = 0.033, Fig 2). These findings suggest 
 
Fig. (1). 8-OHdG according to the subtypes of ischemic stroke, 
lacunar  (LAC),  atherothrombotic  (AT),  and  cardioembolic  (CE) 
infarction  groups.  8-OHdG  for  AT  was  significantly  increased 
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that more oxidative stress would be generated in stroke pa-
tients with more risk factors for arteriosclerosis, reflecting 
poor outcome. 
3.2. Relationship Between Clinical Outcome and Urinary 
8-OHdG 
  Next, we investigated whether urinary 8-OHdG concen-
trations  reflected  the  severity  and  outcome  of  ischemic 
Table 1.  Characteristics of Patients Recruited in This Study 
 
Lacunar  Atherothrombotic  Cardioembolic  P value 
(n=9)  (n=22)  (n=13)   
Age  74  69  74  0.298 
Male/female  5/4  8/14  7/6  0.826 
Previous stroke, % (n)  44 (4)  18 (4)  8 (1)  0.103 
Atrial fibrillation, % (n)  11 (1)  18 (4)  85 (11)  0.001> 
Risk factors for arteriosclerosis         
  Hypertension, % (n)  100 (9)  73 (16)  15 (2)  0.001> 
  Diabetes mellitus, % (n)  0 (0)  36 (8)  8 (1)  0.029 
  Hyperlipidemia, % (n)  22 (2)  50 (11)  23 (3)  0.171 
  Number of risk factors  1.2  1.6  0.5  0.002 
Time from onset to arrival (h)  19.1  16.5  5.1  0.014 
Baseline NIHSS  4  7  19  0.003 
mRS at discharge  1.9  2.6  3.7  0.065 
  mRS ≥3, % (n)  33.3 (3)  50.0 (11)  84.6 (11)  0.038 
Length of stay (days)  28  29  39  0.028 
8-OHdG concentration (ng/mgCr)         
  Day 0  15.8 ± 6.9  12.8 ± 11.7  11.8 ± 5.6  0.128 
  Day 7  16.1 ± 5.1  16.2 ± 15.5  13.0 ± 5.0  0.272 
 
 
Fig. (2). Relationship between Δ 8-OHdG and risk factors for arteriosclerosis. Stroke patients with diabetes mellitus DM), hyperlipidemia 
(HL), or high body mass index (BMI) showed the increased 8-OHdG. HT; hypertension. 54     The Open Neurology Journal, 2012, Volume 6  Nakajima et al. 
stroke. When comparing patients with a poor outcome (mRS 
≥3) and a good outcome (mRS ≤2), no significant differences 
were observed for age, history of previous stroke and atrial 
fibrillation, and prevalence of risk factors for arteriosclerosis 
(Table  2).  Among  patients  with  cardioembolic  infarctions, 
significantly more number of patients had a poor outcome. 
Accordingly,  NIHSS  scores  at  admission  were  higher  and 
the time from onset to arrival was shorter in patients with a 
poor  outcome.  There  was  no  significant  difference  in  8-
OHdG concentrations on Day 0 between patients with poor 
and good outcomes, and 8-OHdG concentrations increased 
on Day 7 in both groups (Table 2). As shown in Fig (3), pa-
tients with a poor outcome had a significantly increased 8-
OHdG  compared  to  those  with  a  good  outcome  (2.54  vs 
39.44,  p  =  0.004).  These  findings  suggested  that  the  bio-
chemical  changes  related  to  8-OHdG  and  oxidative  stress 
may be considered  a  marker of ischemic brain injury and 
clinical outcome of ischemic stroke. 
3.3.  Effect  of  Edaravone  Treatment  on  Urinary  8-
OHdG 
  On comparing the patients treated with or without edara-
vone, no significant differences were observed for age, stro-
ke subtypes, and risk factors for arteriosclerosis (Table 3). 
Based  on  NIHSS  scores,  patients  who  received  edaravone 
tended to be classified as more severe at admission compared 
to those who did not receive edaravone (11.1 vs 6.1); how-
ever, both showed equivalent mRS scores at discharge (2.5 
vs 2.7). Although there was no significant difference in8-
OHdG levels between patients treated with or without edara-
vone, 8-OHdG in patients who received edaravone tended 
to be reduced compared to those who did not receive edara-
vone within the atherothrombotic infarction group (23.5 vs 
46.5, p = 0.433, Fig 4). 
4. DISCUSSION 
  In  order  to  evaluate  ischemic  brain  damage,  numerous 
biomarkers related to oxidative stress, such as nitric oxide, 
matrix metalloproteinase-9, S100 and oxidized LDL, have 
been investigated [19-22]. The main finding of our study is 
the  demonstration  of  an  association  between  urinary  8-
OHdG and ischemic stroke. The present study provides evi-
dence that  8-OHdG, specifically the rate of change of uri-
nary 8-OHdG, may be considered a marker of tissue injury 
in brain ischemia. In fact, mRS scores (i.e., clinical outcomes 
at  discharge)  showed  a  significant  correlation  with  8-
OHdG (Fig 3). These findings suggest that 8-OHdG may 
act as a mediator during the evolution of ischemic damage.  
Table 2.  Demographics and 8-OHdG Concentrations of Patients with Good and Poor Outcomes 
 
Good (mRS ≤2)  Poor (mRS ≥3)  P value 
(n=19)  (n=25)     
Age  70  72  0.541 
Male/female  12:07  13:12  0.066 
Stroke subtypes       
  LAC/AT/CE (n)   6/11/2   3/11/11  0.038 
Previous stroke, % (n)  21 (4)  20 (5)  1.000 
Atrial fibrillation, % (n)  26 (5)  44 (11)  0.344 
Risk factors for arteriosclerosis       
  Hypertension, % (n)  68 (13)  60 (15)  0.753 
  Diabetes mellitus, % (n)  26 (5)  20 (5)  0.723 
  Hyperlipidemia, % (n)  32 (6)  44 (11)  0.535 
  Number of risk factors  1.3  1.2  0.697 
Baseline NIHSS  3.7  14.1  0.001 
Time from onset to arrival (h)  15.8  12.3  0.177 
Edaravone, % (n)  74 (14)  80 (20)   
8-OHdG concentration (ng/mgCr)       
  Day 0  12.1 ± 6.3  13.3 ± 11.2  0.538 
  Day 7  12.8 ± 6.1  17.1 ± 14.1  0.205 
8-OHdG (%) 2.54  39.44  0.004 
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  In all 3 subtypes of ischemic stroke, lacunar, atherothro-
mbotic, and cardioembolic infarctions, urinary 8-OHdG lev-
els  increased  on  Day  7.  When  we  compared  the  rate  of 
change  of  urinary  8-OHdG  (  8-OHdG),  8-OHdG  was 
significantly  higher in patients in the  atherothrombotic in-
farction group than that of patients in the lacunar infarction 
group (Fig 1). Moreover, 8-OHdG of patients in the lacu-
nar infarction group tended to be lower than that of patients 
in  the  cardioembolic  infarction  group,  suggesting  that  a 
smaller  infarction  volume  can  result  in  lesser  amounts  of 
oxidative stress. However, the questions arise as to why 8-
OHdG  increased  more  in  the  atherothrombotic  infarction 
than in the cardioembolic infarction group. 
  Numerous  studies  have  shown  that  urinary  8-OHdG  is 
not only a biomarker of oxidative stress but also a possible 
risk factor for cancer, coronary heart disease, diabetes, and 
atherosclerosis [23,24]. For example, elevated levels of uri-
nary 8-OHdG have been detected in patients with diabetes 
mellitus  or  hypertension  [25].  In  human  atherosclerotic 
plaques,  increased  amounts  of  oxidatively  modified  DNA 
and 8-OHdG are present [26]. Thus, DNA oxidative stress 
may readily occur in patients with these conditions. In this 
study, the atherothrombotic infarction group had more num-
ber of risk factors for arteriosclerosis, such as hypertension, 
diabetes mellitus, and hyperlipidemia, and the cardioembolic 
group had less number of risk factors than the other groups 
(Table  1).  In  addition,  the  risk  factors  for  arteriosclerosis 
such as diabetes mellitus, hyperlipidemia, and BMI influence 
on a production of the oxidative stress (Fig 2). Thus, patients 
with  atherothrombotic  infarctions  may  have  some  back-
ground  conditions  for  which  8-OHdG  is  easily  generated, 
and more increased oxidative damage may cause poor out-
come comparable to that of patients with cardioembolic in-
farctions, despite having the less infarction volume. 
  There is increasing evidence for the contributions of oxi-
dative stress to ischemic brain damage in primary and sec-
ondary pathophysiological mechanisms [1,2]. In addition to 
the direct cytotoxic effects of lipid peroxidation and oxida-
tive  DNA  damage  that  occurs  immediately  after  ischemic 
injury, the burst of free radicals also induces formation of 
inflammatory  mediators  through  redox-mediated  signaling 
pathways, leading to post-ischemia/reperfusion inflammato-
ry injury [4,6]. Therefore, the control of these 2 impacts of 
oxidative damage is important to achieve neuroprotection.  
  Recent  studies  demonstrated  that  edaravone  provided 
neuroprotection  in  the  integrated  processes  of  oxidative 
stress-induced injury in ischemic stroke [27,28]. Edaravone 
has  antioxidant  properties  that  result  in  suppressing  lipid 
peroxidation products and oxidative DNA damage, as well 
as anti-inflammatory effects that result in reduced iNOS pro-
duction [29-33]. Further studies by using animal model sug-
gested that a combination therapy with edaravon and tissue 
plasminogen activator (rt-PA) could provide important ther-
apeutic benefits for acute stroke patients, not only in reduc-
ing the infarct size but also in minimizing the catastrophic 
hemorrhagic  transformation.  In  these  studies,  edaravone 
suppressed  matrix  metalloproteinase-9  (MMP-9)  upregura-
tion and hemorrhagic transformation by scavenging rt-PA-
induced  reactive  oxidative  stress  derived  from  ische-
mia/reperfusion injury [34,35]. 
  As the present study  was not a randomized trial, there 
could have been a bias in the selection of patients for edara-
vone use. However, although patients who received edara-
vone tended to be classified as more severe based on NIHSS 
scores at admission than those who did not receive edara-
vone,  both  groups  showed  equivalent  mRS  scores  at  dis-
charge (Table 3). Furthermore, 8-OHdG levels in patients 
who received edaravone tended to be reduced compared to 
those who did not receive edaravone within the atherothrom-
botic  infarction  group  (Fig  4).  Thus,  edaravone  treatment 
might provide a neuroprotective effect by reducing oxidative 
damage and it may contribute to limiting brain damage. 
 
Fig. (3). Relationship between 8-OHdG and mRS scores at dis-
charge. Patients with a poor outcome (mRS 3≤) had a significantly 
increased 8-OHdG compared to those with a good outcome (mRS 
2≥). 
 
Fig.  (4).  Effect  of  edaravone  on  8-OHdG  in  atherothrombotic 
infarction. 8-OHdG in patients who received edaravone tended to 
be reduced compared to those who did not receive edaravone. 56     The Open Neurology Journal, 2012, Volume 6  Nakajima et al. 
5. CONCLUSION 
  The present study demonstrated a significant association 
between elevated urinary 8-OHdG levels and acute ischemic 
stroke,  especially  for  those  with  atherothrombotic  infarc-
tions. Because  8-OHdG, the rate of change of urinary 8-
OHdG, showed a significant relationship to mRS scores at 
discharge,  8-OHdG may be a useful predictor of poor out-
comes after ischemic stroke. Edaravone is useful for reduc-
ing  oxidative  damage,  especially  in  patients  with  athero-
thrombotic infarctions, and thus, it may contribute to limiting 
brain damage in patients with ischemic stroke. 
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